Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

Condition(s) studied

Investigational drug(s) / intervention(s)

Zilebesiran: Zilebesiran will be administered SC

Placebo: Placebo will be administered SC

Study summary

The purpose of this study is to evaluate whether zilebesiran versus placebo reduces the risk of cardiovascular (CV) death, nonfatal myocardial infarction (MI), nonfatal stroke, or heart failure (HF) events. This is an event-driven study that will continue until the targeted number of positively adjudicated primary endpoint clinical outcome events (COEs) have been reached.

Eligibility

Primary outcome measure(s)

• Time to First Occurrence of a Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, or Heart Failure (HF) Event (Hospitalization for HF or Urgent HF Visit) — Up to approximately 5 years

Trial sites (1153)

+ 1113 more sites — see the full list on the official registry below.

More Alnylam Pharmaceuticals trials in Italy

Other trials for the same condition